| Autor: |
Sarles, J, Barthellemy, S, Férec, C, Iovanna, J, Roussey, M, Farriaux, J P, Toutain, A, Berthelot, J, Maurin, N, Codet, J P, Berthézène, P, Dagorn, J C |
| Zdroj: |
Archives of Disease in Childhood -- Fetal & Neonatal Edition; Mar1999, pF118-F122, 5p |
| Abstrakt: |
Aim: To determine whether pancreatitis associated protein (PAP) is a marker for cystic fibrosis which could be used in neonatal screening for the disease.Methods: PAP was assayed on screening cards from 202,807 neonates. Babies with PAP > or = 15 ng/ml, or > or = 11.5 ng/ml and immunoreactive trypsinogen (IRT) > or = 700 ng/ml were recalled for clinical examination, sweat testing, and cystic fibrosis transmembrane regulator (CFTR) gene analysis.Results: Median PAP value was 2.8 ng/ml. Forty four cases of cystic fibrosis were recorded. Recalled neonates (n = 398) included only 11 carriers. A receiver operating characteristic curve analysis showed that PAP above 8.0 ng/ml would select 0.76% of babies, including all those with cystic fibrosis, except for one with meconium ileus and two with mild CFTR mutations. Screening 27,146 babies with both PAP and IRT showed that only 0.12% had PAP > 8.0 ng/ml and IRT > 700 ng/ml, including all cases of cystic fibrosis.Conclusion: PAP is increased in most neonates with cystic fibrosis and could be used for CF screening. Its combination with IRT looks promising. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
